CHARMS: Couples Health Aging, Rhythms and Sleep Study

Sponsor
University of Utah (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05952284
Collaborator
(none)
340
1
50.4
6.7

Study Details

Study Description

Brief Summary

Alzheimer's disease and related dementias (ADRD), including mild cognitive impairment (MCI), are becoming among the most prevalent causes of disability, death and healthcare costs worldwide. Sleep and circadian rhythm disturbances are common among individuals with MCI as well as their spouses/ partners and may increase risk of the development of ADRD in both patients and partners. This is the first study to systematically investigate sleep as a shared health behavior within couples in which one member has MCI, and the degree to which sleep and circadian disturbances impact both partners health and well-being, including cognitive decline and risk for ADRD.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Individuals with mild cognitive impairment (MCI) demonstrate cognitive decline without major functional impairment but also experience a 7-fold increased risk for developing Alzheimer's disease, a leading cause of poorer quality of life (QOL), premature mortality, and health care expenditures. Sleep and biobehavioral rhythm disturbances (disruptions in 24h oscillations in physiology and behavior, including rest-activity patterns and mealtimes) are more than twice as common among patients with MCI than cognitively intact older adults. Emerging evidence demonstrates a mechanistic role of sleep and biobehavioral rhythm disturbances in cognitive decline and the development and progression of Alzheimer's disease. Importantly, the consequences of sleep and biobehavioral rhythm disruption in MCI extend beyond the patient, also affecting the spouse/partner, as sleep is a "shared" health behavior for most adults. However, sleep and biobehavioral rhythms are typically considered at the level of the individual.

    The overall goal of the study is to investigate sleep and biobehavioral rhythms as fundamental dyadic processes that contribute to the health and cognitive functioning of individuals with MCI or mild AD and their partners. The project will evaluate the daily and longitudinal effects of two dyadic processes in sleep:interdependence (partners' sleep patterns influence on each other) and concordance (i.e., the couples' similarity in rest/activity and social rhythms such as meal timing). The protocol involves a 14-day naturalistic study protocol in order to examine the mechanistic associations between sleep and biobehavioral rhythms and proximal indicators of daytime functioning, within a sample of 170 couples in which one partner evidences cognitive impairment (MCI to mild Alzheimer's disease). During the naturalistic study protocol, measures will capture sleep and biobehavioral rhythms via objective (actigraphy) measures of sleep and circadian rest-activity rhythms and daily social rhythms, respectively. Also, measures include daily assessments of mood and relationship quality and an an innovative smartphone cognitive assessment that has been validated to measure cognitive function in daily life. The longitudinal assessment will include comprehensive neuropsychological assessments at baseline and again at two-year follow-up to examine how sleep and biobehavioral rhythm disruptions at baseline predict cognitive decline over 2 years in both partners.

    Results of study will advance the understanding of the daily and longitudinal relationships between the individual and couple-level processes in sleep and biobehavioral rhythms that influence the progression of cognitive decline in a population at increased risk for developing Alzheimer's disease.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    340 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Couples Health Aging, Rhythms and Sleep Study (CHARMS Study)
    Anticipated Study Start Date :
    Jul 21, 2023
    Anticipated Primary Completion Date :
    Jul 21, 2025
    Anticipated Study Completion Date :
    Oct 2, 2027

    Outcome Measures

    Primary Outcome Measures

    1. Digit symbol: daily score [This study will evaluate day to day change in digit symbol performance over 10 days.]

      This is a daily measure of attention and processing speed collected via smartphone. Participants will have 5 minutes to complete the items. In this measure, participants match each symbol presented to a number. The goal of the test is to complete the most items in the time allotted.

    2. Memory: daily score [This study will evaluate day to day change in digit symbol performance over 10 days.]

      In this measure, participants will have the opportunity to learn a set of 18 words (30 seconds). These words will be present later in the assessment and participants are asked to recognize whether they are on the list.

    Secondary Outcome Measures

    1. Cogntive function: RBANS total score [We will evaluate change from baseline to two years]

      We will administer a standardized test battery called the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). This test takes approximately 30 min and measures the main domains of cognitive function, including immediate memory, visuospatial/construction, language, attention, delayed memory and effort

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    50 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Married or partnered in a romantic relationship, cohabiting for at least two years

    • age >50

    • smartphone user

    • one partner meets criteria for cognitive impairment without severe impairment in daytime dysfunction according to telephone screening, while other partner must not meet this criteria for impairment.

    Exclusion Criteria:
    • Unstable or severe medical or psychiatric conditions that would interfere with study participation (including but not limited to current cancer treatment, psychosis, history of major stroke, head injury with loss of consciousness >30 min, other neurologic/systemic illness that may affect cognition, alcohol or other substance abuse)

    • current use of antipsychotic or anticonvulsant medications

    • inadequate vision, hearing, or dexterity to participate in the assessment

    • night shift work >1x per month (defined as beginning work after 9:00 pm or work in the overnight hours [12:00 am-5:00 am])

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Utah Salt Lake City Utah United States 84108

    Sponsors and Collaborators

    • University of Utah

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Kelly Glazer Baron, Associate Professor, PhD, MPH, University of Utah
    ClinicalTrials.gov Identifier:
    NCT05952284
    Other Study ID Numbers:
    • IRB_00158095
    First Posted:
    Jul 19, 2023
    Last Update Posted:
    Jul 19, 2023
    Last Verified:
    Jul 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Kelly Glazer Baron, Associate Professor, PhD, MPH, University of Utah
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 19, 2023